North Carolina Governor Josh Stein visited Hope Haven, a Charlotte-based substance abuse rehab center, this week to highlight the ongoing fallout from the state’s landmark opioid lawsuit settlements. The tour underscored how billions in compensation are being redirected toward expanding access to medication-assisted treatment (MAT)—including buprenorphine, naltrexone, and methadone—while addressing systemic gaps in addiction care. With opioid-related deaths still rising in the Southeast (up 12% YoY in NC alone), Stein’s visit marks a pivotal moment in translating legal victories into public health impact. Here’s what the science, local healthcare systems, and funding realities reveal.
Why This Matters: The Opioid Crisis Isn’t Over—But Treatment Is Evolving
The opioid epidemic isn’t just a prescription drug problem—it’s a neurobiological disorder where the brain’s mu-opioid receptors (critical for pain and reward pathways) become dysregulated by chronic opioid exposure. MAT works by agonizing or blocking these receptors to reduce cravings and withdrawal symptoms. Yet, despite FDA approval for these therapies since the 1970s, only 20% of eligible patients in North Carolina receive them, per CDC data from 2025. Stein’s visit signals a shift: settlements are funding mobile MAT clinics and peer navigator programs, but success hinges on overcoming provider shortages and stigma.
In Plain English: The Clinical Takeaway
- MAT isn’t just for heroin users: It’s FDA-approved for prescription opioid use disorder (OUD) too, cutting relapse rates by 50%+ in clinical trials.
- Buprenorphine vs. Methadone: Buprenorphine (e.g., Suboxone) is outpatient-friendly; methadone requires daily clinic visits but has a longer half-life (24–36 hours vs. 24–42 hours for buprenorphine).
- Settlement money ≠ instant access: Only 18% of NC counties have a buprenorphine prescriber, per SAMHSA’s 2026 provider map.
The Science Behind the Settlement: How MAT Actually Works
MAT leverages three pharmacological mechanisms:
- Opioid agonists (methadone, buprenorphine): Mimic opioids but with lower euphoria and longer receptor occupancy, reducing cravings.
- Opioid antagonists (naltrexone): Block receptors entirely, used for post-detox maintenance (requires strict compliance).
- Partial agonists (buprenorphine): Bind receptors less strongly than full agonists, reducing overdose risk while managing withdrawal.
Phase III trials (e.g., NEJM 2020) show buprenorphine reduces all-cause mortality by 30% over 12 months compared to placebo. Yet, only 1 in 5 patients who need MAT ever receive it—a gap the opioid settlements aim to close.
Regional Impact: How NC’s Settlement Compares to National Trends
North Carolina’s $580 million opioid settlement (finalized in 2024) is the second-largest in the U.S., after Ohio’s $800M. Funds are allocated thusly:
| Allocation | NC Funding ($M) | National Avg. (2026) | Impact |
|---|---|---|---|
| MAT Expansion | 300 | 22% of settlements | Adds 500+ new buprenorphine prescribers to NC’s 1,200 current providers. |
| Harm Reduction (naloxone, fentanyl test strips) | 120 | 18% of settlements | Doubles naloxone distribution sites in Charlotte-Mecklenburg. |
| Peer Recovery Coaches | 80 | 10% of settlements | Trains 300+ recovery coaches, critical for retention in MAT (coaches improve adherence by 40%, per JAMA Internal Medicine 2021). |
Critically, NC’s model prioritizes geographic equity: 60% of funds target rural counties (e.g., Robeson, where opioid deaths rose 35% YoY), where MAT access is nearly nonexistent. This mirrors the CDC’s 2026 Rural Opioid Strategy, which identifies transportation barriers and provider deserts as top hurdles.
—Dr. Nora Volkow, Director, NIH National Institute on Drug Abuse (NIDA)
“The opioid settlements are a historic opportunity, but implementation is the bottleneck. We’ve known since the 1990s that MAT saves lives—yet bureaucracy and stigma still block scale. NC’s focus on peer navigators is exactly how we close that gap.”
Funding Transparency: Who’s Behind the Data—and Who Benefits?
The opioid settlements stem from multistate agreements with pharmaceutical distributors (e.g., McKesson, Cardinal Health) and manufacturers (e.g., Johnson & Johnson, Teva). However, only 15% of NC’s funds are earmarked for direct patient care; the rest covers legal fees and infrastructure. This raises questions about return on investment (ROI):
- Pharma’s role: Companies like Indivior (maker of Suboxone) have donated $20M+ to NC’s MAT programs, but conflicts of interest persist. A 2022 NEJM study found pharma-funded MAT clinics were 3x more likely to push buprenorphine over methadone, despite methadone’s superior efficacy for severe OUD.
- Nonprofit oversight: The NC Department of Health and Human Services (NCDHHS) administers funds, but audits reveal delays in disbursing harm-reduction grants. For example, a 2025 GAO report found 40% of naloxone distribution sites in Charlotte were understocked due to logistical bottlenecks.
Expert Consensus: The Hard Truth About MAT Access
—Dr. Kevin Sabet, President, Smart Approaches to Marijuana (SAM)
“MAT works, but we’re still treating addiction like a moral failing. The settlements are a start, but if we don’t train more primary care doctors to prescribe buprenorphine—and fast—we’ll just shift the crisis to unregulated fentanyl markets.”
Contraindications & When to Consult a Doctor
MAT is not a one-size-fits-all solution. Key red flags and contraindications:
- Active liver disease: Methadone and buprenorphine are hepatically metabolized; patients with cirrhosis or hepatitis C require dose adjustments.
- Pregnancy: Buprenorphine is FDA Pregnancy Category C (risk not ruled out), but methadone is Category B and preferred in late-stage pregnancy. Neonatal abstinence syndrome (NAS) risk is 2x higher with abrupt MAT cessation (AJOG 2018).
- Co-occurring psychiatric disorders: Bipolar disorder or schizophrenia may require naltrexone (antagonist) over agonists, but only under specialist supervision.
- History of opioid-induced respiratory depression: Buprenorphine’s ceiling effect (limited respiratory depression) makes it safer than methadone, but titration must be slow in high-risk patients.
When to seek help immediately:
- Overdose symptoms: Pinpoint pupils, slowed breathing (<10 breaths/min), blue lips (signs of opioid toxicity). Administer naloxone (Narcan) and call 911.
- Suicidal ideation: MAT reduces suicide risk by 40% long-term, but withdrawal from antidepressants (common in OUD patients) can trigger acute crises.
- Severe withdrawal: Diarrhea, hypertension >180/120, or hallucinations require medical detox (not self-tapering).
The Road Ahead: Can NC’s Model Work Nationwide?
North Carolina’s approach—combining legal settlements with MAT expansion and peer support—offers a blueprint, but three critical challenges remain:
- Provider pipeline: The U.S. Needs 10,000+ more buprenorphine waivered prescribers to meet demand (NSDUH 2023). Telehealth waivers (expanded in 2021) help, but rural broadband gaps persist.
- Fentanyl’s dominance: 80% of NC opioid deaths now involve fentanyl (CDC 2026), requiring naloxone co-prescription with MAT—a standard not yet universally adopted.
- Long-term funding: Settlement money is one-time. Sustainable MAT programs need Medicaid expansion (NC expanded in 2023) and insurance parity laws (only 22 states mandate coverage for MAT).
The good news? MAT’s cost-effectiveness is undeniable: Every dollar spent on MAT saves $4–$7 in healthcare costs (Health Affairs 2020). Stein’s visit is a reminder that legal accountability must translate to clinical action—but the hard work lies in ensuring no patient falls through the cracks.
References
- Amato L et al. (2020). “Buprenorphine Maintenance vs Placebo for Opioid Dependence.” NEJM.
- Larochelle MR et al. (2021). “Medication-Assisted Treatment and Mortality Among Patients With Opioid Use Disorder.” JAMA Internal Medicine.
- Sordo L et al. (2022). “Pharmaceutical Industry Influence on Medication-Assisted Treatment.” NEJM.
- Jones HE et al. (2018). “Neonatal Abstinence Syndrome After Maternal Use of Buprenorphine or Methadone.” AJOG.
- NSDUH 2023: National Survey on Drug Use and Health. SAMHSA.
Disclaimer: This article is for informational purposes only and not a substitute for professional medical advice. Always consult a healthcare provider for personalized guidance.
